Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| You will note that we are aiming to deliver increased year-over-year product revenue growth while at the same time decreasing our operating expense levels |
| We realized several pivotal milestones, including the launch of DAXXIFY and aesthetics and the FDA approval of DAXXIFY for cervical dystonia in addition to achieving record product revenue of $213 million, up 80% year-over-year |
| So we feel like we're really well positioned in cervical dystonia, and we're also encouraged by some of the payers that are looking at this as sort of a generic category where the approval of DAXXIFY will allow the payers to ultimately manage the category the way that they think makes the most sense, along with the clinicians |
| Combined with our commercial progress to-date, we believe we are well positioned to deliver on our strategic priorities for 2024, which I will cover later in the call |
| But all in all, the team has made tremendous progress in terms of the overall coverage side of it |
| We also gained important real-world feedback from the early stages of our DAXXIFY launch, which informed our updated pricing and provider engagement strategy, better positioning us for broader adoption and long-term success |
| And so we really like sort of the response that we've gotten in the adoption, and we've made great progress with a lot of the top groups there |
| So we feel like at least in CD coming into the market, we've got a really strong position within the commercial payer community in terms of our ability to compete effectively and not have any step edits or limits |
| And so David's always been close to the program, but more on the medical side, and now in sort of the leadership side, we feel really good to have him in that role |
| And so we feel very fortunate to have her leading our aesthetic efforts, and she's doing a great job and has really been intimately involved with a lot of the streamlining efforts that we have made |
| And so, given where we are now at the end of February, we've made really good progress through that, and you'll see us again move to a more normal launch cadences as we get into Q2 |
| So I feel we've made a really good, really good progress there |
| Beyond pricing, we consistently hear from customers that DAXXIFY is a great product and offers a compelling value proposition because of its unique peptide formulation, fast onset, long duration and ability to enhance the skin's appearance |
| But we feel like the first thing to do is prove out the business model, continue the track record of success that we've had growing DAXXIFY, RHA with the cost structure that we've outlined here, and that will unlock continued opportunities through either organic or sort of other financing alternatives |
| The new messaging, along with expanded sales tools and materials was shared with our sales team at our National Sales Meeting in January, and has been very well received |
| I'm excited about the product |
| But we've been very pleased to see the receptivity of this both at the account level and on the patient level and it's having the desired effect of generating more trial usage and experience |
| But we think that this is really an encouraging gateway for us into the broader therapeutics market, and we really like where we're positioned |
| Further, in February, we executed one of several planned promotional programs, a patient coupon program, which has been very well received and aligns with our goal of driving greater practice and consumer experience with DAXXIFY |
| And so given the data that we generated in our ASPEN clinical program, our ability to potentially give them many more symptom-free days, both from an early onset of action, along with a good duration profile has been incredibly well received by both clinicians and payers |
| We believe RHA's success can be attributed to not only our strong execution, but more importantly, it's leading innovation |
| But when we've done the roll up and put together our plan, we feel very good about the guidance that we put out there |
| And then obviously, we believe very strongly in medical education and training |
| The lips are the most frequently treated area for dermal fillers and the recently approved label expansion provides us with new opportunities to train on RHA's leading innovation and injection techniques |
| In 2023, we were pleased to deliver a 20% year-over-year RHA revenue growth despite softness in the U.S |
| And again, given sort of the number of accounts that we still have to go -- we feel good about it |
| Also given where we are in our journey, we have plenty of opportunity to continue to grow our share, and we've been the fastest-growing share taker over the last 3 years, and we feel very good about the technology and where we're positioned in the market |
| And with our expanded portfolio of different RHA filler lines and the expanded indications, we feel very good about how we're positioned in the market |
| Based on our clinical trial data and early PrevU experience, we believe that DAXXIFY has the potential to provide patients with better symptom control, along with a compelling safety profile |
| And so we feel very good about -- if you look at how RHA and Teoxane has performed internationally in a very competitive market, how they've been able to continue to take share and to grow it |
| Statement |
|---|
| Quarterly sales were down 1% year-over-year, primarily due to higher-than-normal RHA sales recorded in Q4 of 2022 |
| Since patients can't get reinjected until 12 weeks due to label and reimbursement restrictions, this can leave CD patients with significant treatment gaps when considering both the delayed onset of action and early wear off |
| Only then, I feel I'm missing out on opportunities to drive more awareness |
| Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties |
Please consider a small donation if you think this website provides you with relevant information